KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (IS) (2020 - 2026)

AbCellera Biologics filings provide 7 years of Depreciation & Amortization (IS) readings, the most recent being $6.8 million for Q1 2026.

  • Quarterly Depreciation & Amortization (IS) rose 28.27% to $6.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.7 million through Mar 2026, down 74.08% year-over-year, with the annual reading at $22.2 million for FY2025, 75.6% down from the prior year.
  • Depreciation & Amortization (IS) hit $6.8 million in Q1 2026 for AbCellera Biologics, up from $6.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $36.9 million in Q3 2024 and bottomed at $4.0 million in Q1 2022.
  • Average Depreciation & Amortization (IS) over 5 years is $10.1 million, with a median of $5.6 million recorded in 2023.
  • The largest annual shift saw Depreciation & Amortization (IS) skyrocketed 551.02% in 2024 before it crashed 85.79% in 2025.
  • AbCellera Biologics' Depreciation & Amortization (IS) stood at $13.8 million in 2022, then tumbled by 45.46% to $7.5 million in 2023, then surged by 66.73% to $12.6 million in 2024, then tumbled by 51.27% to $6.1 million in 2025, then increased by 11.68% to $6.8 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Depreciation & Amortization (IS) are $6.8 million (Q1 2026), $6.1 million (Q4 2025), and $5.2 million (Q3 2025).